Adjuvant Endocrine Therapy for Women with Hormone Receptor Positive Breast Cancer Guideline

BCI: Guideline-Recognized and Validated to Help Guide Extended Endocrine DecisionsПодробнее

Cancer Topics - ASCO Guidelines: Role of Patient and Disease Factors in Adjuvant Systemic Therapy...Подробнее

ASCO Guidelines: Adjuvant Endocrine Therapy for Women with Hormone Receptor Positive Breast Cance...Подробнее

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision-Making for Early-Stage,...Подробнее

Use of Biomarkers to Guide Decisions on Adjuvant Therapy for Early-Stage Invasive Breast Cancer G...Подробнее

Abemaciclib with Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optima...Подробнее

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer GuidelineПодробнее

Contrasting Cases: TAILORx- Chemotherapy or no?Подробнее

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer Guideline UpdateПодробнее

Adjuvant Endocrine Therapy for high-risk breast cancerПодробнее

The Predictive Power of the Breast Cancer Index (H/I) Biomarker-SABCS 2022Подробнее

HER2-Negative Breast Cancer | Beyond the Guidelines: Clinical Investigator Perspectives on the Ma...Подробнее

Conceptualizing Guidelines to Manage Patients with HR–Positive, HER2-Negative Early Breast CancerПодробнее

Management of Male Breast Cancer GuidelineПодробнее

Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFTПодробнее

Neoadjuvant Endocrine Therapy in Breast CancerПодробнее

Education Session: Trends in Adjuvant Endocrine TherapyПодробнее

How to Manage the Side Effects of Hormonal Therapy for Breast CancerПодробнее

ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-WynneПодробнее